What happened in this Health story?

The Trump administration is funding the first U.S. clinical trials of ibogaine for opioid addiction and PTSD, while AstraZeneca opens a new 570,000-square-foot R&D center in Cambridge, Mass., as part of a $50 billion investment push.

What is a key fact in this story? (1)

**The Trump administration** is advancing the first government-funded clinical trials of ibogaine to treat opioid addiction and PTSD, following an April executive order that dedicated $50 million to federal ibogaine research.

What is a key fact in this story? (2)

**The FDA** opened a public docket seeking feedback on ibogaine trial design, dose selection, patient eligibility, safety monitoring, study-stopping rules, and oversight, with comments due Nov. 20.

📎 SkimNews has covered Trump administration 197+ times · see the file →

U.S. Funds Ibogaine Trials; AstraZeneca Opens Boston R&D Center — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-06

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

The Trump administration is advancing the first government-funded clinical trials of ibogaine to treat opioid addiction and PTSD, following an April executive order that dedicated $50 million to federal ibogaine research.
The FDA opened a public docket seeking feedback on ibogaine trial design, dose selection, patient eligibility, safety monitoring, study-stopping rules, and oversight, with comments due Nov. 20.
AstraZeneca opened a new 570,000-square-foot, 18-story R&D center in Cambridge, Mass.'s Kendall Square biotech cluster, the centerpiece of a $1 billion Massachusetts investment program.
The Cambridge facility sits within AstraZeneca's broader ~$50 billion investment program, first announced in 2024 and "dramatically expanded" last year.
Veterans and experts have called for strict safety standards on psychedelic treatments as the federally backed ibogaine trial push gains momentum.

Why it matters: AstraZeneca's 570,000-square-foot Kendall Square facility anchors a $1 billion Massachusetts investment within a broader $50 billion program, while the FDA's Nov. 20 ibogaine docket deadline gives researchers, veterans, and drugmakers a narrow window to shape the design of the first federally funded psychedelic trial.